Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00332553 · ClinicalTrials.gov registry record · Phase 2
Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00332553 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 150 participants.
The verdict
NCT00332553, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
This pilot study was designed to explore the effects of combined treatment with raloxifene HCl 60 mg and oral 17 beta-estradiol 1mg/day on the number of vasomotor episodes (hot flashes plus night sweats) in postmenopausal women discontinuing continuous combined hormone replacement therapy (ccHRT) compared to women treated with raloxifene HCl 60 mg alone.
Interventions
- DRUG Raloxifene
- DRUG medroxyprogesterone acetate
- DRUG estrogen
- DRUG 17 beta estradiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2002-02 |
| Est. Completion | 2004-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00332553
The ClinicalTrials.gov registry entry for NCT00332553 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Raloxifene is the first listed.
NCT00332553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00332553 about?
NCT00332553 is a clinical study titled "Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen". This pilot study was designed to explore the effects of combined treatment with raloxifene HCl 60 mg and oral 17 beta-estradiol 1mg/day on the number of vasomotor episodes (hot flashes plus night sweats) in postmenopausal women discontinuing continuous combined hormone replacement therapy (ccHRT) co...
What is the current status of trial NCT00332553?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2002-02. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00332553?
The interventions under investigation include: Raloxifene (DRUG), medroxyprogesterone acetate (DRUG), estrogen (DRUG), 17 beta estradiol (DRUG).
Who is sponsoring clinical trial NCT00332553?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.